Ampersand Capital Partners, a private equity firm, agreed to acquire Biologos, a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Financial terms were not disclosed. "This is an exciting time at Biologos as we have experienced impressive growth thanks to our team's ability to provide high-quality standard and custom biologics solutions for our customers. Ampersand's deep industry expertise, broad network, and capital resources will enable Biologos to accelerate its growth strategy through the development of new products and its expansion into new markets," Tony Bazarko, Biologos CEO.